Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste)

NCT05176717 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

TERMINATED

Status

5

Enrollment

INDUSTRY

Sponsor class

Stopped Business decision

Conditions

Retinitis Pigmentosa
Usher Syndrome Type 2
Deaf Blind
Retinal Disease
Eye Diseases
Eye Diseases, Hereditary
Eye Disorders Congenital
Vision Disorders

Interventions

DRUG: QR-421a
OTHER: Sham-procedure

Sponsor

Laboratoires Thea

Collaborators

[object Object]